Has the Hong Kong Pharma Industry valuation changed over the past few years?

Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 24.2x which is higher than its 3-year average PE of 18.5x. The industry is trading close to its 3-year average PS ratio of 1.2x.

Which industries have driven the changes within the Hong Kong Healthcare industry?

There are no additional sub-industries under this industry.

Hong Kong (HSI) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 29 Jul 2026	HK$676.3b	HK$522.4b	HK$28.0b	14.4x	24.2x	1.3x
Fri, 26 Jun 2026	HK$596.3b	HK$520.2b	HK$29.2b	12.9x	20.4x	1.1x
Sun, 24 May 2026	HK$696.9b	HK$520.8b	HK$29.6b	14.4x	23.6x	1.3x
Tue, 21 Apr 2026	HK$789.9b	HK$518.8b	HK$30.0b	15x	26.3x	1.5x
Thu, 19 Mar 2026	HK$753.7b	HK$501.5b	HK$30.4b	12.3x	24.8x	1.5x
Sat, 14 Feb 2026	HK$816.3b	HK$497.4b	HK$30.5b	13.3x	26.8x	1.6x
Mon, 12 Jan 2026	HK$849.6b	HK$491.3b	HK$30.1b	13.4x	28.2x	1.7x
Wed, 10 Dec 2025	HK$826.4b	HK$484.8b	HK$29.7b	13.5x	27.8x	1.7x
Fri, 07 Nov 2025	HK$805.2b	HK$480.5b	HK$29.8b	14x	27x	1.7x
Sun, 05 Oct 2025	HK$816.5b	HK$479.6b	HK$30.6b	13.7x	26.7x	1.7x
Tue, 02 Sep 2025	HK$822.7b	HK$479.7b	HK$30.6b	13x	26.9x	1.7x
Thu, 31 Jul 2025	HK$775.3b	HK$475.3b	HK$29.1b	12.1x	26.7x	1.6x
Sat, 28 Jun 2025	HK$632.6b	HK$475.9b	HK$28.7b	11.3x	22x	1.3x
Mon, 26 May 2025	HK$558.7b	HK$477.8b	HK$29.2b	10.7x	19.2x	1.2x
Wed, 23 Apr 2025	HK$501.7b	HK$465.4b	HK$28.5b	10x	17.6x	1.1x
Fri, 21 Mar 2025	HK$488.7b	HK$465.3b	HK$32.2b	9x	15.2x	1.1x
Sun, 16 Feb 2025	HK$430.0b	HK$463.6b	HK$32.0b	8.6x	13.5x	0.9x
Tue, 14 Jan 2025	HK$397.1b	HK$459.0b	HK$31.7b	7.9x	12.5x	0.9x
Thu, 12 Dec 2024	HK$446.3b	HK$462.3b	HK$31.9b	8.4x	14x	1x
Sat, 09 Nov 2024	HK$445.9b	HK$468.6b	HK$32.5b	8.5x	13.7x	1x
Mon, 07 Oct 2024	HK$532.0b	HK$474.8b	HK$33.0b	8.3x	16.1x	1.1x
Wed, 04 Sep 2024	HK$437.9b	HK$472.5b	HK$32.8b	7.8x	13.3x	0.9x
Fri, 02 Aug 2024	HK$418.6b	HK$459.5b	HK$32.6b	7.5x	12.8x	0.9x
Sun, 30 Jun 2024	HK$438.9b	HK$461.3b	HK$33.7b	8.2x	13x	1x
Tue, 28 May 2024	HK$470.1b	HK$462.7b	HK$33.7b	8.7x	14x	1x
Thu, 25 Apr 2024	HK$445.0b	HK$464.2b	HK$33.8b	7.4x	13.2x	1x
Sat, 23 Mar 2024	HK$460.6b	HK$470.2b	HK$32.8b	7.8x	14x	1x
Mon, 19 Feb 2024	HK$433.2b	HK$471.0b	HK$33.6b	7x	12.9x	0.9x
Wed, 17 Jan 2024	HK$443.6b	HK$471.5b	HK$33.7b	7.4x	13.2x	0.9x
Fri, 15 Dec 2023	HK$482.0b	HK$472.6b	HK$33.8b	7.8x	14.3x	1x
Sun, 12 Nov 2023	HK$487.0b	HK$469.2b	HK$31.9b	7x	15.3x	1x
Tue, 10 Oct 2023	HK$428.1b	HK$469.8b	HK$31.6b	6.8x	13.5x	0.9x
Thu, 07 Sep 2023	HK$425.5b	HK$469.7b	HK$31.6b	6.8x	13.5x	0.9x
Sat, 05 Aug 2023	HK$471.8b	HK$446.4b	HK$27.9b	9x	16.9x	1.1x


HK Market	0.77%
Healthcare	0.12%
Pharma	-1.06%
Pharma	-1.06%

Company	Last Price	7D	1Y	Valuation
2630 Vigonvita Life Sciences	HK$90.00	35.1% +HK$3.9b	n/a	PS127.6x
6887 Sunshine Lake Pharma	HK$36.30	11.1% +HK$2.1b	-39.7%	PE66.3x
1093 CSPC Pharmaceutical Group	HK$8.49	1.0% +HK$914.6m	-14.0%	PE25.7x
3320 China Resources Pharmaceutical Group	HK$4.84	1.5% +HK$439.8m	-14.0%	PE6.5x
460 Sihuan Pharmaceutical Holdings Group	HK$0.93	3.3% +HK$270.7m	-32.6%	PE40.3x

Announcement • Jul 24

Grand Pharmaceutical Group Limited Announces First Patient Enrolled and Dosed in the Phase Iiiclinical Trial

The Board of Grand Pharmaceutical Group Limited announced that the first patient was enrolled and dosed in the Phase IIIclinical trial conducted in China of the Group's innovative traditional Chinese medicine ("TCM") GPN01360 for the treatment of depression recently. It marks a significant milestone for the Group in the direction of Chinese patent medicine in the field of the ENT (Ear, Nose, and Throat) segment. This study was a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial that plans to enroll 480 patients with depression. Patients received oral administration for 8 weeks. It aims to evaluate the efficacy, safety and tolerance of GPN01360 compared to placebo in treating depression (liver stagnation and spleen deficiency syndrome). The primary clinical endpoint was the change in the total score of the Hamilton Depression Rating Scale ("HAMD-17") from baseline at week 8; secondary endpoints included efficacy and safety metrics such as the change in the total score of the Montgomery-Asberg Depression Rating Scale ("MADRS") from baseline at week 8, the HAMD-17 remission rate and response rate at week 8, the change in the Pittsburgh Sleep Quality Index ("PSQI") score from baseline at week 8, the changes in the Clinical Global Impression Scale-Disease Severity (CGI-S) scores from baseline and Clinical Global Impression Scale-Overall Improvement (CGI-I) scores, and the incidence of adverse events. GPN01360 is a Class 1.1 innovative TCM for the treatment of depression (liver stagnation and spleen deficiency syndrome). It is a TCM innovation achievement which R&D received key supported from the national "Major New Drug Development Project". Based on the ancient classic formula "Xiaoyaosan()", it was developed and optimized through modern pharmacological and clinical research. The prescription consists of 12 TCM herbs, including Bupleurum, Turmeric Root Tuber, and Finger Citron, with the effects of soothing the liver and strengthening the spleen, relieving depression, and calming the mind. This TCM is mainly used to treat depression of the liver stagnation and spleen deficiency type, of which the typical symptoms include low mood, slow thinking, decreased willpower, irritability, anxiety, insomnia, forgetfulness, poor appetite, and fatigue. The completed Phase II clinical trial showed that GPN01360 has favorable safety and efficacy in the treatment of depression, and has a significant improvement in symptoms such as depression accompanied by anxiety and insomnia. Depression, also known as depressive disorder, is a common mental disorder that can affect a patient's work, study, and social life. In severe cases, it can lead to suicide, and the relapse rate is as high as 75%-90%. It is a lifelong illness and the leading cause of the global mental health burden, representing a major global public health problem. According to the latest statistics from the World Health Organization (WHO), approximately 332 million people worldwide suffer from depressive disorder, with an overall prevalence of about 4.0%, of which the prevalence in adults reaches 5.7%. Depressive disorder is the second leading cause of years lived with disability ("YLDs") globally, and the leading cause of YLDs in the 15-29 age group. It places a huge burden on global social productivity, with depression and anxiety resulting in 12 billion lost workdays and nearly USD 1 trillion in economic losses annually. The China Mental Health Survey shows that the prevalence of depressive disorder among adults in China is 6.8%, which is higher than the global average, with a total of over 90 million people affected. Currently, the clinical cure rate for depressive disorder is less than 30%, and clinical treatment still faces several bottlenecks. For example, the delayed efficacy of commonly used antidepressants means suicide risk cannot be controlled quickly, and adverse drug reactions can affect patient adherence. Therefore, there remains a significant unmet clinical need for the treatment of depression, and the Group's GPN01360 is expected to provide a novel clinical treatment option. As one of the major ENT drug R&D, production and sales integrated enterprises in China, the Group ranks among the top in the industry in terms of the number of product pipelines. Its treatment areas include diseases in multiple fields such as ophthalmology, otolaryngology, and stomatology, covering chemical preparations, Chinese drug preparations and health products, including prescription drugs, OTC drugs, medical devices, consumer goods and other major categories. It has established a professional marketing team and formed a nationwide marketing network. Chinese patent medicine is a key direction in the field of the Group's ENT segment. Leveraging the core advantages of TCM in chronic disease treatment, the Group continues to cultivate the Chinese patent medicine market. While consolidating and improving its ENT product matrix, the Group has successfully expanded its business into the treatment of cerebro-cardiovascular chronic diseases and neurology by strategically developing several TCM with significant competitive advantages. This has enabled the Group to achieve a strategic transformation of its Chinese patent medicine business from a single-focus area of ENT to a comprehensive chronic disease treatment approach. Leveraging the powerful synergistic effects of its "carrier-cluster" product pipeline, the Group not only continues to expand its leading advantage in the existing ENT field, but also actively explores new chronic disease treatment areas such as cardiology and neurology, aiming to systematically broaden the treatment boundaries of chronic disease management and open up new growth avenues. The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs, enrich its product pipeline and improve supply chain capabilities. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.Provide your feedback on BizChat.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Antengene Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026

New minor risk - Insider selling

CSPC Pharmaceutical Group Limited Announces Acceptance Of New Drug Application For Sirolimus For Injection (Albumin-Bound) By NMPA

Sihuan Pharmaceutical Holdings Group Ltd. Announces Change of Address of Registered Office and Principal Share Registrar in Bermuda

Grand Pharmaceutical Group Limited Announces First Patient Enrolled and Dosed in the Phase Iiiclinical Trial

Alebund Pharmaceuticals (Jiangsu) Limited Randomizes and Doses First Participant in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia in Patients Receiving Maintenance Hemodialysis

New minor risk - Share price stability

New minor risk - Share price stability

China Medical System Holdings Limited Obtains Drug Clinical Trial Approval For CMS-D017 Capsules For Age-Related Macular Degeneration

Fujian Haixi Pharmaceuticals Co., Ltd. Announces Approval of HXP089 Investigational New Drug Application for Treatment of Glioblastoma

China Resources Pharmaceutical Group Limited Announces Board Changes, Effective July 13, 2026

Hansoh Pharmaceutical Group Company Limited Reports Positive Phase III Results For Risvutatug Rezetecan In Small-Cell Lung Cancer

New minor risk - Market cap size

Sino Biopharmaceutical Limited Submits New Drug Application for Ropivacaine Hydrochloride Sustained-Release Solution

Ocumension Therapeutics Announces Resignation of Tim Ruan as Chief Financial Officer, Effective June 30, 2026

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2026 Results on Aug 26, 2026